Enalivex reports positive results in a clinical trial of Allocetra for the treatment of corona patients in severe/critical condition
Enlivex Therapeutics, an immunotherapy company in the clinical trial phase, today reports positive results in a clinical trial of Allocetra for the treatment of corona patients in severe/critical condition.
The clinical trial included five Covid-19 patients, three of them in serious condition and two others in critical condition. All five patients recovered completely from the previous condition and were discharged from the hospital after an average of 5.5 days (patients in serious condition) and 8.5 days (patients in critical condition) after starting treatment with Allocetra. All patients received a negative result in the corona test at the time of discharge. No serious side effects were reported as a result of Allocetra treatment, and the treatment was defined as tolerable.
The company states that treatments such as plasma-based antibodies are usually given to patients in moderate condition. Allocetra, if approved, could potentially cover the gap, and would treat patients in severe/critical condition.
Based on the positive results from the first five corona patients in severe/critical condition, alongside positive results of safety and effectiveness in the use of Allocetra in 10 sepsis patients in a previous trial, the company decided to divert the recruitment of additional patients to an expanded phase 2 trial in corona patients in severe/critical condition, early As much as possible, after regulatory approval.
Prof. Vernon van Heerden, director of the intensive care unit at Hadassah Hospital in Israel and the main researcher of the Corona and sepsis trials, stated that "to date we have treated 15 patients with Allocetra at the hospital, 10 of them with sepsis and 5 with Corona is in serious or critical condition. Based on the preliminary results that showed safety and indication of Allocetra's effectiveness in patients with these complications, Enlivex's Allocetra product has the potential to help corona patients in severe/critical condition."
Prof. Dror Mbaruch, Enlivex's medical director, added: "The results of Allocetra treatment in severe and critical corona patients reflect a unique opportunity for Enlivex to contribute to efforts to fight the ongoing global epidemic of the corona virus. It seems that the initial positive results observed in sepsis patients treated with Allocetra were translated to corona patients in severe and critical condition."
All trials in Corona are planned to be conducted separately from the planned phase IIb trial in Allocetra for the treatment of system collapse as a result of sepsis. The aforementioned trial will be controlled and randomized, which is expected to begin by the fourth quarter of 2020.
More of the topic in Hayadan:
- The search for cures for corona gets a boost from discoveries about the Sars virus
- Researchers from the Hebrew University and Mount Sinai Hospital in New York cracked the replication mechanism of the corona virus and found an existing drug that attacks it
- A drug given to Gaucher patients blocks the replication of the corona virus in the cell
4 תגובות
When the immune system gets out of control, a cytokine storm occurs - repeated feeding that increases the secretion of protein more and more - which causes a severe disorder in the respiratory system. The treatment is an injection of 'almost dead' cells, the macrophages eat them and signal to the immune system that it can lower its alertness and relax.
https://www.enlivex.com/investor-relations/#latest-news
At the moment the news is first, for some reason it is not possible to click directly on the link to the article.
Everything is fine and dandy, but there is no detail about the treatment itself, just by the way.
Are these antibodies from plasma? A synthetic molecule?
You can get this article in English (want to pass it on to friends in Europe...)